Deakin University
Browse

File(s) not publicly available

The effects of inhaled beclomethasone dipropionate on lung function and histamine responsiveness in recurrently wheezy infants

journal contribution
posted on 1995-01-01, 00:00 authored by S M Stick, P R Burton, J B Clough, M Cox, P N LeSouef, Peter Sly
Inhaled steroids improve pulmonary function and bronchial responsiveness in older asthmatics. Data from studies using subjective outcome measures to determine the effectiveness of inhaled steroids in infants with recurrent wheezing are equivocal. Therefore, this study tested the hypothesis that beclomethasone dipropionate improves pulmonary function, including bronchial responsiveness to histamine, in recurrently wheezy infants. The study was double blind, placebo controlled lasting nine weeks. After the first baseline week, pulmonary function was measured using the rapid thoracoabdominal compression technique and bronchial responsiveness assessed with a histamine challenge test. Infants were then randomly allocated to receive doses of placebo or beclomethasone dipropionate (100 μg/puff) from metered aerosols. Two puffs of test aerosol were administered twice daily for eight weeks via a large volume spacer fitted with a facemask. Symptoms were recorded daily and pulmonary function and bronchial responsiveness assessed at the end of the treatment period; 50 infants, median age 12 months (range 5 to 18 months), were recruited. Twenty three in the beclomethasone dipropionate group and 15 in the placebo group completed the study and had pairs of pulmonary function measurements. Three were probable treatment failures (one beclomethasone dipropionate, two placebo), three were possible treatment failures (placebo), and others were non-compliant with study protocol. Baseline variables were not significantly different between those Australia infants who completed the study and those who did not. Beclomethasone dipropionate and placebo groups were similar in all respects at baseline. Lung function and improved for both groups during the study. Bronchial responsiveness increased significantly in the placebo group but there were no statistically significant differences between groups for any of the other outcome measures. It is concluded that beclomethasone dipropionate (400 μg daily) via a large volume spacer does not significantly improve lung function or symptoms in recurrently wheezy infants but might have a beneficial bronchial responsiveness.

History

Journal

Archives of Disease in Childhood

Volume

73

Issue

4

Pagination

327 - 332

ISSN

0003-9888

eISSN

1468-2044

Usage metrics

    Research Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC